Business Model Breakdown
How CorMedix Inc Makes Money
CRMD
Market Cap
$646M
Annual Revenue
$91M
Profit Margin
45.3%
Employees
64
The Short Version
CorMedix develops and commercializes specialty pharmaceutical products, primarily focused on preventing and treating infectious diseases in acute care and hemodialysis settings. Their flagship product, DefenCath, is a first-in-class antimicrobial catheter lock solution designed to prevent catheter-related bloodstream infections in hemodialysis patients, generating significant revenue. The company also sells a portfolio of anti-infective products acquired from Melinta Therapeutics and is advancing additional pipeline candidates for other supportive care indications, targeting chronic and acute care segments through direct sales to hospitals and dialysis centers.
Where the Revenue Comes From
DefenCath Sales (~76% of Q1 2026 net revenue, or $97.5M)
Melinta Portfolio Sales (~24% of Q1 2026 net revenue, or $29.9M)
Who buys: Hospitals, dialysis centers, clinics, and other healthcare providers specializing in acute care and chronic conditions requiring catheter-based interventions.
Why It Works (Competitive Advantages)
- ✔First-in-class FDA approved DefenCath with QIDP exclusivity for CRBSI prevention.
- ✔Strong clinical data backing DefenCath's efficacy and safety.
- ✔Diversifying pipeline (REZZAYO, taurolidine/heparin study) expanding TAM beyond DefenCath.
Economic Moat: Narrow (Intangible Assets/IP (DefenCath's regulatory exclusivity and patent protection), Switching Costs (Potential for DefenCath to become the standard of care in dialysis centers))
What Our Analysis Says
DVR Score as of June 5, 2026
CorMedix Inc. exhibits significantly de-risked commercialization with exceptional Q1 2026 results, reporting $127.4 million in revenue and $38.6 million in net income, handily beating revenue estimates. The company substantially raised its FY2026 guidance to $325M-$345M revenue and $115M-$135M adjusted EBITDA, demonstrating strong market adoption of DefenCath and effective integration of the Melinta portfolio. This transition from a promising approval to a profitable, rapidly growing entity reinforces its 10x potential. While execution risks remain in scaling operations and advancing pipeline assets, the clear path to establishing DefenCath as a standard of care, coupled with a robust balance sheet and positive cash flow, provides a compelling investment thesis. The increased market cap to $0.67B still leaves substantial room for appreciation against the updated guidance and future growth drivers.